Entrada’s Duchenne study remains on hold in US as biotech completes dosing of two cohorts in UK trial

En­tra­da Ther­a­peu­tics an­nounced that it com­plet­ed dos­ing for two co­horts for a Phase I study of an ex­per­i­men­tal Duchenne mus­cu­lar dy­s­tro­phy drug that it’s con­duct­ing in the UK while the US IND is still on hold.

In Wednes­day’s up­date, En­tra­da said it pro­vid­ed ad­di­tion­al in­for­ma­tion to the FDA, but the agency de­clined to lift the hold that was an­nounced in De­cem­ber of last year. In an email to End­points News, the com­pa­ny said it would not share spe­cif­ic de­tails on the hold in the US but not­ed that it ex­pects the Phase I da­ta from the UK to sup­port a “glob­al clin­i­cal tri­al strat­e­gy that will in­clude the US.” En­tra­da’s stock $TR­DA fell 24% on the news to be­low $13 a share.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.